# Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI

> **NCT00537056** · NA · COMPLETED · sponsor: **Stanford University** · enrollment: 17 (actual)

## Conditions studied

- Kidney Neoplasms
- Carcinoma, Renal Cell
- Kidney (Renal Cell) Cancer

## Interventions

- **PROCEDURE:** FDG PET CT
- **PROCEDURE:** DCE MRI
- **DRUG:** F-18 Fluoro-deoxi-glucose
- **DRUG:** Gadolinium-DTPA
- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT00537056
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2011-10
- **Final completion:** 2012-04
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2017-06-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00537056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00537056, "Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00537056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*